Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Conversion of Monoclonal Igg to Dimeric and Secretory Iga Restores Neutralizing Ability and Prevents Infection of Omicron Lineages Publisher Pubmed



Marcotte H1 ; Cao Y2, 3 ; Zuo F1 ; Simonelli L4 ; Sammartino JC5 ; Pedotti M4 ; Sun R1 ; Cassaniti I5 ; Hagbom M6 ; Piralla A5 ; Yang J7 ; Du L1 ; Percivalle E5 ; Bertoglio F8 Show All Authors
Authors
  1. Marcotte H1
  2. Cao Y2, 3
  3. Zuo F1
  4. Simonelli L4
  5. Sammartino JC5
  6. Pedotti M4
  7. Sun R1
  8. Cassaniti I5
  9. Hagbom M6
  10. Piralla A5
  11. Yang J7
  12. Du L1
  13. Percivalle E5
  14. Bertoglio F8
  15. Schubert M8
  16. Abolhassani H1
  17. Sherina N1
  18. Guerra C4
  19. Borte S9, 10
  20. Rezaei N11
  21. Kumagaibraesch M12
  22. Xue Y13
  23. Su C14
  24. Yan Q15
  25. He P15
  26. Gronwall C16
  27. Klareskog L16, 17
  28. Calzolai L18
  29. Cavalli A4
  30. Wang Q19
  31. Robbiani DF4
  32. Hust M8
  33. Shi Z20
  34. Feng L15
  35. Svensson L6, 21
  36. Chen L22
  37. Bao L23, 24
  38. Baldanti F5, 25
  39. Xiao J2, 14
  40. Qin C23, 24
  41. Hammarstrom L1
  42. Yang X7
  43. Varani L4
  44. Xie XS2, 3
  45. Panhammarstrom Q1

Source: Proceedings of the National Academy of Sciences of the United States of America Published:2024


Abstract

The emergence of Omicron lineages and descendent subvariants continues to present a severe threat to the effectiveness of vaccines and therapeutic antibodies. We have previously suggested that an insufficient mucosal immunoglobulin A (IgA) response induced by the mRNA vaccines is associated with a surge in breakthrough infections. Here, we further show that the intramuscular mRNA and/or inactivated vaccines cannot sufficiently boost the mucosal secretory IgA response in uninfected individuals, particularly against the Omicron variant. We thus engineered and characterized recombinant monomeric, dimeric, and secretory IgA1 antibodies derived from four neutralizing IgG monoclonal antibodies (mAbs 01A05, rmAb23, DXP-604, and XG014) targeting the receptor-binding domain of the spike protein. Compared to their parental IgG antibodies, dimeric and secretory IgA1 antibodies showed a higher neutralizing activity against different variants of concern (VOCs), in part due to an increased avidity. Importantly, the dimeric or secretory IgA1 form of the DXP-604 antibody significantly outperformed its parental IgG antibody, and neutralized the Omicron lineages BA.1, BA.2, and BA.4/5 with a 25-to 75-fold increase in potency. In human angiotensin converting enzyme 2 (ACE2) transgenic mice, a single intranasal dose of the dimeric IgA DXP-604 conferred prophylactic and therapeutic protection against Omicron BA.5. Thus, dimeric or secretory IgA delivered by nasal administration may potentially be exploited for the treatment and prevention of Omicron infection, thereby providing an alternative tool for combating immune evasion by the current circulating subvariants and, potentially, future VOCs. © 2024 the Author(s).
Other Related Docs
15. Heterologous Inactivated Virus/Mrna Vaccination Response to Bf.7, Bq.1.1, and Xbb.1, The Lancet Regional Health - Western Pacific (2023)